FDA Clears Metagenomi's MGX-001 IND for Hemophilia A; Cash Runway Extended Into 2028
MGX sits 20% above its 52-week low of $0.6.
Summary
Metagenomi won FDA clearance for its MGX-001 hemophilia A IND and reported Q3 cash of $101.7 million, enough to fund operations into 2028 while the INTEGR8 trial starts in the first half of 2027.
Key Events · Product Development and Regulatory · MGX
-
FDA Clears MGX-001 IND
The FDA cleared the IND for MGX-001, Metagenomi's lead wholly owned hemophilia A gene editing program, allowing the INTEGR8 Phase 1/2 trial to begin in the U.S.
-
Cash Runway Extended Into 2028
Cash, cash equivalents and available-for-sale marketable securities were $101.7 million at September 30, 2026, versus $160.8 million at December 31, 2025; management now expects runway to support operations into 2028.
-
Q3 Burn and Cost Cuts
R&D expense fell to $17.5 million from $25.3 million a year earlier, while G&A rose to $6.9 million including a $1.2 million one-time net litigation settlement; net loss was $21.1 million, or $0.56 per share.
-
Trial Timeline and ASH Data
Metagenomi plans to start the INTEGR8 trial in the first half of 2027 and report initial safety, tolerability and FVIII activity data in the second half of 2027; additional preclinical data will be presented at ASH on December 14, 2026.
Analysis · MGX · Life Sciences
The FDA clearance moves Metagenomi's lead wholly owned program from preclinical into the clinic — the first real test of whether its albumin-locus gene insertion platform works in humans. That matters more than the quarter's numbers: the company burned $22.2 million in Q3 and ended September with $101.7 million, which management now says funds operations into 2028, past the planned INTEGR8 trial start in the first half of 2027 and initial data in the second half. The trade-off is time: investors wait roughly a year for the first human safety and Factor VIII activity readout, with the ASH preclinical presentation on December 14, 2026 as the nearest checkpoint.
How filings like this one have moved
In the 30 days to Nov 11, 2026, 48.1% of the 1752 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.29%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MGX was trading at $0.72 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $26.4M. The 52-week trading range was $0.60 to $2.28. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.